Heron Therapeutics logo

Heron Therapeutics (HRTX) Q1 2026 Earnings

HRTX·Reported May 11, 2026·Before market open

Heron Therapeutics reported Q1 2026 revenue of $34.7M (-10.8% YoY), missed analyst consensus of $36.7M by $2.0M. Diluted EPS came in at $-0.04, missed the $-0.03 consensus by $0.01.

Revenue
$34.7Mmissed by $2.0M
Consensus: $36.7M
Diluted EPS
$-0.04missed by $0.01
Consensus: $-0.03
SEC

SEC Filings

Earnings release8-K · 0001193125-26-215752
Quarterly report10-Q · 0001193125-26-215755

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Heron Therapeutics's Q1 2026 earnings report.

Heron Therapeutics (HRTX) reported Q1 2026 earnings on May 11, 2026 before market open.

Heron Therapeutics reported revenue of $34.7M and diluted EPS of $-0.04 for Q1 2026.

Revenue missed the consensus estimate of $36.7M by $2.0M. EPS missed the consensus estimate of $-0.03 by $0.01.

Compared to the same quarter a year prior, revenue declined 10.8% from $38.9M a year earlier.

You can read the 8-K earnings release (0001193125-26-215752) and the 10-Q periodic report (0001193125-26-215755) directly on SEC EDGAR. The filing index links above go to sec.gov.